Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 26346 | 9.19 |
09:34 ET | 300 | 9.15 |
09:36 ET | 1470 | 9.1 |
09:38 ET | 3295 | 9.2062 |
09:39 ET | 450 | 9.23 |
09:41 ET | 1300 | 9.28 |
09:43 ET | 526 | 9.2794 |
09:45 ET | 636 | 9.26 |
09:48 ET | 500 | 9.3 |
09:50 ET | 511 | 9.32 |
09:52 ET | 1606 | 9.3593 |
09:54 ET | 1100 | 9.375 |
09:56 ET | 1126 | 9.39 |
09:57 ET | 300 | 9.36 |
09:59 ET | 1812 | 9.37 |
10:01 ET | 2446 | 9.405 |
10:03 ET | 6272 | 9.36 |
10:06 ET | 1586 | 9.4 |
10:08 ET | 1164 | 9.37 |
10:10 ET | 3473 | 9.36 |
10:12 ET | 400 | 9.37 |
10:14 ET | 3578 | 9.345 |
10:15 ET | 2152 | 9.36 |
10:17 ET | 1968 | 9.37 |
10:19 ET | 13187 | 9.33 |
10:21 ET | 1100 | 9.295 |
10:24 ET | 4143 | 9.27 |
10:26 ET | 1333 | 9.32 |
10:28 ET | 1010 | 9.31 |
10:30 ET | 36151 | 9.2 |
10:32 ET | 3722 | 9.246 |
10:33 ET | 400 | 9.22 |
10:35 ET | 2150 | 9.22 |
10:37 ET | 2506 | 9.21 |
10:39 ET | 11946 | 9.2 |
10:42 ET | 900 | 9.205 |
10:44 ET | 700 | 9.2 |
10:46 ET | 5478 | 9.21 |
10:48 ET | 1384 | 9.21 |
10:50 ET | 400 | 9.21 |
10:51 ET | 600 | 9.2 |
10:53 ET | 3460 | 9.2 |
10:55 ET | 400 | 9.2 |
10:57 ET | 526 | 9.205 |
11:00 ET | 9264 | 9.22 |
11:02 ET | 2900 | 9.24 |
11:04 ET | 3648 | 9.26 |
11:06 ET | 1798 | 9.2968 |
11:08 ET | 1800 | 9.3 |
11:09 ET | 982 | 9.29 |
11:11 ET | 2159 | 9.255 |
11:13 ET | 500 | 9.235 |
11:15 ET | 500 | 9.22 |
11:18 ET | 1059 | 9.23 |
11:20 ET | 1100 | 9.25 |
11:22 ET | 956 | 9.265 |
11:24 ET | 1200 | 9.3 |
11:26 ET | 1149 | 9.28 |
11:27 ET | 2450 | 9.25 |
11:29 ET | 1135 | 9.26 |
11:31 ET | 10465 | 9.28 |
11:33 ET | 600 | 9.26 |
11:36 ET | 1860 | 9.26 |
11:38 ET | 500 | 9.27 |
11:40 ET | 500 | 9.26 |
11:42 ET | 4617 | 9.28 |
11:45 ET | 16594 | 9.27 |
11:47 ET | 5520 | 9.3 |
11:49 ET | 8848 | 9.325 |
11:51 ET | 2430 | 9.31 |
11:54 ET | 4132 | 9.3365 |
11:56 ET | 1128 | 9.33 |
11:58 ET | 1029 | 9.3378 |
12:00 ET | 3431 | 9.335 |
12:02 ET | 500 | 9.32 |
12:05 ET | 1630 | 9.31 |
12:07 ET | 550 | 9.31 |
12:09 ET | 950 | 9.32 |
12:12 ET | 1830 | 9.32 |
12:14 ET | 8838 | 9.3 |
12:16 ET | 17423 | 9.3 |
12:18 ET | 100 | 9.3 |
12:20 ET | 3992 | 9.31 |
12:21 ET | 400 | 9.32 |
12:23 ET | 200 | 9.315 |
12:25 ET | 500 | 9.3 |
12:27 ET | 400 | 9.32 |
12:30 ET | 1852 | 9.31 |
12:32 ET | 933 | 9.3 |
12:34 ET | 1450 | 9.3 |
12:36 ET | 200 | 9.3 |
12:38 ET | 4932 | 9.3 |
12:39 ET | 3714 | 9.3 |
12:41 ET | 2000 | 9.3 |
12:43 ET | 2120 | 9.28 |
12:45 ET | 800 | 9.27 |
12:48 ET | 1550 | 9.275 |
12:50 ET | 7964 | 9.28 |
12:52 ET | 200 | 9.27 |
12:54 ET | 1886 | 9.3 |
12:56 ET | 300 | 9.31 |
12:57 ET | 1038 | 9.3 |
12:59 ET | 2682 | 9.3 |
01:01 ET | 1000 | 9.3 |
01:03 ET | 200 | 9.3 |
01:06 ET | 5015 | 9.29 |
01:08 ET | 100 | 9.29 |
01:10 ET | 1787 | 9.27 |
01:12 ET | 1870 | 9.285 |
01:14 ET | 5804 | 9.23 |
01:15 ET | 1178 | 9.235 |
01:17 ET | 4913 | 9.25 |
01:19 ET | 4226 | 9.24 |
01:21 ET | 1000 | 9.22 |
01:24 ET | 1304 | 9.2 |
01:26 ET | 300 | 9.19 |
01:28 ET | 1413 | 9.21 |
01:30 ET | 2937 | 9.23 |
01:32 ET | 10277 | 9.195 |
01:33 ET | 500 | 9.19 |
01:35 ET | 1487 | 9.18 |
01:37 ET | 3497 | 9.16 |
01:39 ET | 1300 | 9.1535 |
01:42 ET | 8088 | 9.09 |
01:44 ET | 450 | 9.09 |
01:46 ET | 400 | 9.09 |
01:48 ET | 2600 | 9.09 |
01:50 ET | 16325 | 9.08 |
01:51 ET | 987 | 9.06 |
01:53 ET | 19077 | 9.0204 |
01:55 ET | 9900 | 9.03 |
01:57 ET | 3553 | 9.07 |
02:00 ET | 6240 | 9.07 |
02:02 ET | 602 | 9.07 |
02:04 ET | 2687 | 9.09 |
02:06 ET | 2316 | 9.09 |
02:08 ET | 13513 | 9.09 |
02:09 ET | 1000 | 9.09 |
02:11 ET | 6300 | 9.1101 |
02:13 ET | 3087 | 9.11 |
02:15 ET | 4106 | 9.1153 |
02:18 ET | 8944 | 9.15 |
02:20 ET | 5900 | 9.15 |
02:22 ET | 3777 | 9.14 |
02:24 ET | 3310 | 9.155 |
02:26 ET | 3226 | 9.1505 |
02:27 ET | 1600 | 9.155 |
02:29 ET | 5525 | 9.15 |
02:31 ET | 900 | 9.15 |
02:33 ET | 500 | 9.15 |
02:36 ET | 1615 | 9.155 |
02:38 ET | 4466 | 9.18 |
02:40 ET | 3305 | 9.18 |
02:42 ET | 1686 | 9.17 |
02:44 ET | 2072 | 9.16 |
02:45 ET | 300 | 9.165 |
02:47 ET | 4034 | 9.17 |
02:49 ET | 3251 | 9.17 |
02:51 ET | 2393 | 9.15 |
02:54 ET | 1200 | 9.14 |
02:56 ET | 500 | 9.155 |
02:58 ET | 6023 | 9.13 |
03:00 ET | 1135 | 9.13 |
03:02 ET | 4241 | 9.12 |
03:05 ET | 900 | 9.12 |
03:07 ET | 4344 | 9.1 |
03:09 ET | 300 | 9.1 |
03:12 ET | 300 | 9.09 |
03:14 ET | 602 | 9.09 |
03:16 ET | 3000 | 9.08 |
03:18 ET | 1445 | 9.075 |
03:20 ET | 7230 | 9.09 |
03:21 ET | 1639 | 9.11 |
03:23 ET | 2904 | 9.11 |
03:25 ET | 7012 | 9.1075 |
03:27 ET | 1913 | 9.1 |
03:30 ET | 3283 | 9.105 |
03:32 ET | 3502 | 9.115 |
03:34 ET | 1400 | 9.12 |
03:36 ET | 10086 | 9.119 |
03:38 ET | 1200 | 9.12 |
03:39 ET | 2852 | 9.11 |
03:41 ET | 4673 | 9.115 |
03:43 ET | 5161 | 9.1005 |
03:45 ET | 6862 | 9.12 |
03:48 ET | 11673 | 9.125 |
03:50 ET | 4946 | 9.11 |
03:52 ET | 12254 | 9.115 |
03:54 ET | 7947 | 9.125 |
03:56 ET | 14988 | 9.1 |
03:57 ET | 16951 | 9.09 |
03:59 ET | 52236 | 9.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.3B | -2.3x | --- |
Nurix Therapeutics Inc | 1.2B | -7.7x | --- |
Prothena Corporation PLC | 1.1B | -6.1x | --- |
Immatics NV | 1.2B | -11.3x | --- |
Arcutis Biotherapeutics Inc | 1.1B | -3.2x | --- |
Silence Therapeutics PLC | 930.9M | -16.7x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 15.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.